Globalization of Alzheimer's disease clinical trials

Alzheimer's Research and Therapy

Volumn 3, Issue 4, 2011, Pages

  Cummings, Jeffrey ^a   Reynders, Robert ^b   Zhong, Kate ^a  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^b Touro College of Osteopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CYTOCHROME P450; NOOTROPIC AGENT;

AGING; ALLELE; ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); CULTURAL ANTHROPOLOGY; DIET; DISEASE REGISTRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; EDUCATIONAL STATUS; ETHNICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE QUALITY; HUMAN; NUTRITION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; UNITED STATES;

EID: 80555137490     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt86     Document Type: Review

References (47)

1. A Wimo, M Prince, World Alzheimer Report 2010: The Global Economic Impact of Dementia London: Alzheimer's Disease International 2010
2. A new global view. The use of foreign data in INDs requires rethinking clinical trials. K Phelps, V Kumar, Drug Discov Dev 2011 30 32
3. Clinical trials in India. RMR Maiti, Pharmacol Res 2007 56 1 10 10.1016/j.phrs.2007.02.004 17391981 (Pubitemid 46990927)
4. Relevance of outcome measures in different cultural groups-does one size fit all? HF Chui, LC Lam, Int Psychogeriatr 2007 19 457 466 10.1017/ S1041610207004838 17346362 (Pubitemid 46707420)
5. World Health Organization, The World Medicines Situation Geneva: World Health Organization 2004
6. Ethical and scientific implications of the globalization of clinical research. SW Glickman, JG McHutchinson, ED Peterson, CB Cairns, RA Harington, RM Calif, KA Schulman, N Engl J Med 2009 360 816 823 10.1056/NEJMsb0803929 19228627
7. The Establishment of Emerging Trial Regions. JPE Karlberg, Clinical Trial Magnifier 2011 4 7 23
8. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? JL Cummings, Biol Psychiatry 2010 68 876 878 10.1016/j.biopsych.2010.09.020 21035622
9. International Conference on Harmonisation; Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data; Availability. Food and Drug Administration, Federal Register 1998 63 31790 31796 10180134
10. Human Development Report, The Real Wealth of Nations: Pathways to Human Development United Nations Development Program 2010
11. Comparison of electrocardiographic findings and associated risk factors between Taiwan Chinese and US White adults. CC Wu, WT Yeh, RS Crow, CH Bai, WH Pan, Int J Cardiol 2008 128 224 231 10.1016/j.ijcard.2007.05.038 17655945 (Pubitemid 352037461)
12. Education Level Statistics. http://www.nationmaster.com/index.php
13. The Cognitive Subscale of Alzheimer's Assessment Scale, Chinese version in staging of Alzheimer disease. H Wang, X Yu, S Li, Y Chen, H Li, J He, Alzheimer Dis Assoc Disord 2004 18 231 235 15592136 (Pubitemid 40076154)
14. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. RC Petersen, PS Aisen, LA Beckett, MC Donohue, AC Gamst, DJ Harvery, CR Jack Jr, WJ Jugust, LM Shaw, AW Toga, JQ Trojanowski, MW Weiner, Neurology 2010 74 201 209 10.1212/WNL.0b013e3181cb3e25 20042704
15. Rate of memory decline in AD is related to education and occupation. Y Stern, S Albert, MX Tang, WY Tsai, Neurology 1999 53 1942 1947 10599762
16. Education modifies the relation of AD pathology to level of cognitive function in older persons. DA Bennett, RS Wilson, JA Schneider, DA Evans, CF Mendes de Leon, SE Arnold, LL Barnes, JL Bienias, Neurology 2003 60 1909 1915 12821732 (Pubitemid 36736005)
17. Alzheimer disease and cognitive reserve. CM Roe, MA Mintun, G D'Angelo, C Xiong, EA Grant, JC Morris, Arch Neurol 2008 65 1467 1471 10.1001/archneur.65. 11.1467 19001165
18. Interaction of neuritic plaques and education predicts dementia. CM Roe, C Xiong, JP Miller, NJ Cairns, JC Morris, Alzheimer Dis Assoc Disord 2008 22 188 193 10.1097/WAD.0b013e3181610fff 18525294
19. Cognitive reserve hypothesis: Pittsburgh compound b and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. NM Kemppainen, S Aalto, M Karrasch, K Nagren, N Savisto, V Oikonen, R Parkkola, J Rinne, Ann Neurol 2008 63 112 118 10.1002/ana.21212 18023012 (Pubitemid 351240557)
20. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. KY Liang, MA Mintun, AM Fagan, AM Goate, JM Bigg, DM Holtzman, JC Morris, D Head, Ann Neurol 2010 68 311 318 10.1002/ana.22096 20818789
21. Stature and status: height, ability and labor market outcomes. A Case, C Paxson, J Polit Econ 2008 116 499 532 10.1086/589524 19603086
22. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. K Ichimaru, S Toyoshima, Y Uyama, Clin Pharmacol Ther 2010 87 362 366 10.1038/clpt.2009.285 20107436
23. Challenges in the clinical development requirements for the marketing authorization of new medicines in Sutheast Asia. A Kudrin, J Clin Pharmacol 2009 49 268 280 10.1177/0091270008329557 19168433
24. A review and assessment of potential sources of ethnic differences in drug responsiveness. TD Bjornsson, JA Wagner, SR Donahue, D Harper, A Karim, M Khouri, WR Murphy, K Roman, D Schneck, DS Sonnichsen, DJ Stalker, SD Wise, S Dombey, C Loew, J Clin Pharmacol 2003 43 943 967 10.1177/0091270003256065 12971027 (Pubitemid 37022739)
25. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. WE Faison, SK Schultz, J Aerssens, J Alvidrez, R Anand, LA Farrer, L Jarvik, J Manly, T McCrae, GM Murphy Jr, JT Olin, M Regier D Sano, JE Mintzer, Internat Psychogeriatr 2007 19 539 558 10.1017/S104161020700511X (Pubitemid 46707427)
26. APOE distribution in world populations with new data from India and the UK. PP Singh, M Singh, SS Mastana, Ann Hum Biol 2006 33 279 308 10.1080/03014460600594513 17092867 (Pubitemid 44232589)
27. Cerebral atrophy, apolipoprotein E 4 and rate of decline in everyday function among patients with amnestic mild cognitive impairment. OC Okonkwo, ML Alosco, BA Jerskey, LH Sweet, BR Ott, G Tremont, the Alzheimer's Disease Neuroimaging Initiative, Alzheimers Dement 2010 6 404 411 10.1016/j.jalz.2010. 02.003 20813341
28. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE 4/4 genotype. ES Blom, V Giedratis, H Zetterberg, H Fukumoto, K Blennow, B Hyman, MC Irizarry, LO Wahlund, L Lannfelt, M Ingelsson, Dement Geriatr Cogn Disord 2009 27 458 464 10.1159/000216841 19420940
29. Head circumference as a measure of cognitive reserve. Association with severity of impairment in Alzheimer's disease. AB Graves, JA Mortimer, EB Larson, A Wenzlow, JD Bowen, WC McCormick, Br J Psychiatry 1996 169 86 92 10.1192/bjp.169.1.86 8818374
30. The protective role of brain size in Alzheimer's disease. JL Whitwell, Expert Rev Neurother 2010 10 1799 1801 10.1586/ern.10.168 21091311
31. Behavioral disorders in Alzheimer's disease: a transcultural perspective. G Binetti, MS Mega, E Magni, A Padovani, L Rozzini, G Lussignoli, A Bianchetti, M Trabucchi, J Cummings, Arch Neurol 1998 55 539 544 10.1001/archneur.55.4.539 9561983 (Pubitemid 28182701)
32. Trends in prevalence of Alzheimer's disease and vascular dementia in a Japanese community: the Hisayama Study. A Sekita, T Ninomiya, Y Tanizaki, Y Doi, J Hata, K Yonemoto, H Arima, K Sasaki, M Iida, T Iwaki, S Kanba, Y Kiyohara, Acta Psychiatr Scand 2010 122 319 325 10.1111/j.1600-0447.2010.01587.x 20626720
33. Neuropsychiatric symptoms of Alzheimer's disease differ in Chinese and American patients. TW Chow, CK Liu, JL Fuh, VP Leung, CT Tai, LW Chen, SJ Wang, HF Chiu, LC Lam, QL Chen, JL Cummings, Int J Geriatr Psychiatry 2002 17 22 28 10.1002/gps.509 11802226 (Pubitemid 34121092)
34. The need for a consensus in the use of assessment tools for Alzheimer's disease: the feasibility study (assessment) tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium (EADC) survey. SPR Diaz, PG Gregorio, JMR Casdado, E Reynich, PJ Ousset, B Vellas, E Salmon, EADC centers and investigators, Int J Geriatr Psychiatry 2005 20 744 748 10.1002/gps.1355 16035121 (Pubitemid 41158719)
35. Administration and scoring variance on the ADAS-cog. DJ Connor, MN Sabbagh, J Alzheimers Dis 2008 15 461 464 18997299
36. Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials. DJ Connor, MN Sabbagh, JL Cummings, Alzheimers Dem 2008 4 390 394 10.1016/j.jalz.2008.09.002
37. Global issues in drug development for Alzheimer's disease. RS Doody, PE Cole, DS Miller, E Siemers, R Black, H Feldman, R Schindler, S Graham, T Heath, AS Khachaturian, R Evans, MC Carrillo, Alzheimers Dement 2011 7 197 207 10.1016/j.jalz.2011.01.001 21414556
38. Sample size requirements for training to a k agreement criterion on clinical dementia ratings. RE Tractenberg, F Yumoto, S Jin, JC Morris, Alzheimer Dis Assoc Disord 2010 24 264 268 20473138
39. US Department of Health and Human Services-Office of Inspector General, The Globalization of Clinical Trials. A Growing Challenge in Protecting Human Subjects. OEI-01-0-00190 2001 1 51
40. Proposals of statistical consideration to evaluation for a specific region in multi-regional trials-Asian perspective. H-H Tsou, S-C Chow, G Lan, J-p Liu, M Wang, H-D Chern, L-T Ho, CA Hsiung, C-F Hsaio, Pharm Stat 2010 9 201 206 10.1002/pst.442 20568264
41. Clinical trials for drug registration in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective. WJ Shih, Controlled Clin Trials 2001 22 357 366 10.1016/S0197-2456(01)00138-6 11514037 (Pubitemid 32763102)
42. US Department of Health and Human Services-Food and Drug Administration, Guidance for Industry: E5-Ethnic Factors in the Acceptability of Foreign Clinical Data, Questions, and Answers 2006 1 8
43. European Medicines Agency, ICH Topic e 5 (R1): Note for Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data-Step 5 1998 1 15
44. Practical issues and observations on the use of foreign clinical data in drug development. M Goto, T Hamasaki, J Biopharm Stat 2002 12 369 384 10.1081/BIP-120014566 12448578 (Pubitemid 35332822)
45. US Department of Health and Human Services-Food and Drug Administration, Guidance for Industry: Acceptance of Foreign Clinical Studies 2001 1 2
46. US Department of Health and Human Sevices-Office Inspector General, Challenges to FDA's Ability to Monitor and Inspect Foreign Clinical Trials. OEI-01-08-00501 2010 1 43 21835281
47. Study design considerations: conducting global clinical trials in early Alzheimer's disease. RJ Schindler, J Nutr Health Aging 2010 14 312 314 10.1007/s12603-010-0071-4 20306004